Allogene Therapeutics (ALLO) Return on Capital Employed (2018 - 2026)
Allogene Therapeutics (ALLO) posted Return on Capital Employed of 50.37% for Q1 2026, up 4.86% sequentially from 52.95% in Q4 2025, and up 358.0% YoY from 11.0% in Q1 2025.
Allogene Therapeutics (ALLO) Return on Capital Employed (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Return on Capital Employed for 9 years, with the latest figure at 50.37% in Q1 2026.
- Quarterly Return on Capital Employed rose 358.0% year-over-year to 50.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 50.37% (up 358.0% YoY) and the FY2025 annual result came in at 46.54%, up 223.0% from the prior year.
- Return on Capital Employed advanced to 50.37% in Q1 2026 per ALLO's latest filing, from 52.95% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 23.22% in Q1 2022 and troughed at 55.57% in Q2 2025.
- A 5-year average of 46.21% and a median of 50.71% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed plunged 2560 bps in 2023, then soared 358 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 41.72% in 2022, then declined by 23 bps to 51.13% in 2023, then fell by 0 bps to 51.22% in 2024, then fell by 3 bps to 52.95% in 2025, then advanced by 5 bps to 50.37% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 50.37%, 52.95%, and 53.71% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -40.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.86% |
| Mar 31, 2026 | -50.37% |
| Dec 31, 2025 | -52.95% |
| Sep 30, 2025 | -53.71% |
| Jun 30, 2025 | -55.57% |
| Mar 31, 2025 | -53.96% |
| Dec 31, 2024 | -51.22% |
| Sep 30, 2024 | -50.87% |
| Jun 30, 2024 | -49.89% |
| Mar 31, 2024 | -51.08% |
| Dec 31, 2023 | -51.13% |
| Sep 30, 2023 | -48.04% |
| Jun 30, 2023 | -50.71% |
| Mar 31, 2023 | -48.81% |
| Dec 31, 2022 | -41.72% |
| Sep 30, 2022 | -27.07% |
| Jun 30, 2022 | -25.21% |
| Mar 31, 2022 | -23.22% |
| Dec 31, 2021 | -17.72% |
| Sep 30, 2021 | -23.94% |